The research describes a previously unknown role in the gut for a receptor, DRD2. DRD2 has otherwise been known as a dopamine (neurotransmitter) receptor in the central and peripheral nervous systems.

The decision to acquire Chimerix comes just a few months after Jazz claimed FDA approval for Ziihera (zanidatamab), its ...

Eli Lilly and Company, Chimerix, and Johnson & Johnson are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of companies ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

According to a study published in Nature, gut bacteria and a diet high in the amino acid tryptophan can protect against pathogenic E. coli, which can cause severe upset stomach, cramps, fever ...

Dopamine receptors are a primary target of the SGAs, and many studies have tested whether variation in the dopamine receptor genes correlate with treatment response and/or side effect profiles.

Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to ...